Scangos George A
SEC-identified person · CIK 1202102 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Voyager Therapeutics, Inc. VYGR | Director | filed 2023 - 2026 |
| Agilent Technologies, INC. A | Director | filed 2014 - 2026 |
| Vir Biotechnology, Inc. VIR | Director · President and CEO | filed 2019 - 2025 |
| Exelixis, INC. XEL | Director · President & CEO | filed 2006 - 2020 |
| Biogen INC. BIIB | Director · Chief Executive Officer | filed 2010 - 2016 |
| Anadys Pharmaceuticals INC ANDS | Director | filed 2006 - 2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.